Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours

5 Apr 2019

Abstract excerpt

// Liliana D. Ordonez 1 , Trevor Hay 1 , Robert McEwen 2 , Urszula M. Polanska 2 , Adina Hughes 2 , Oona Delpuech 2 , Elaine Cadogan 2 , Steve Powell 2 , Jonathan Dry 3 , Giusy Tornillo 1 , Lucy Silcock 1 , Elisabetta Leo 2 , Mark J. O’Connor 2 , Alan R. Clarke 1 , * and Matthew J. Smalley 1 1 European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, UK 2 Oncology, IMED Biotech Unit, AstraZeneca,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31080552
DOI: 10.18632/oncotarget.26830

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumoursPMID 31080552Read ↗

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.Semantic proximity Read ↗

Understanding tumour growth variability in patient-derived breast cancer xenograft models identifies early responders and biomarkers of resistance to PARP inhibitionSemantic proximity Read ↗

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.Semantic proximity Read ↗

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancerSemantic proximity Read ↗

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?Semantic proximity Read ↗

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerSemantic proximity Read ↗

BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug ResistanceSemantic proximity Read ↗

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitroSemantic proximity Read ↗

PARP1 inhibition regulates tumor progression through modulation of RhoGDIα and vimentin in triple negative breast cancerSemantic proximity Read ↗

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian CancerSemantic proximity Read ↗

Combination of olaparib and savolitinib overcomes olaparib-resistance in epithelial ovarian cancer modelsSemantic proximity Read ↗

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.